**Background of ADGRF1 Antibody**
ADGRF1 (Adhesion G Protein-Coupled Receptor F1), also known as GPR110. is a member of the adhesion GPCR family, characterized by a large extracellular N-terminal region involved in cell-cell or cell-matrix interactions. It plays roles in cellular signaling, tissue development, and homeostasis, with emerging links to cancer, neurodevelopmental disorders, and metabolic regulation. ADGRF1 antibodies are essential tools for studying the receptor’s expression, localization, and functional mechanisms.
These antibodies are typically designed to target specific epitopes within ADGRF1’s extracellular or intracellular domains, enabling applications such as Western blotting, immunohistochemistry, immunofluorescence, and flow cytometry. Validation often includes testing in ADGRF1-knockout cell lines to confirm specificity. Research using ADGRF1 antibodies has revealed its involvement in pathways like cAMP signaling and cell adhesion, as well as its potential as a biomarker in cancers, including prostate and lung malignancies.
Recent studies also explore ADGRF1’s role in synaptic plasticity and energy homeostasis, highlighting its therapeutic potential. However, challenges remain in understanding its ligand interactions and activation mechanisms. ADGRF1 antibodies thus serve as critical reagents for unraveling the receptor’s physiological and pathological relevance.